Efficacy News and Research

RSS
Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Artisan Pharma enrolls 750 patients in Phase 2b study of ART-123 in sepsis patients with DIC

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

Oncos Therapeutics completes $5.5M investment from HealthCap

Oncos Therapeutics completes $5.5M investment from HealthCap

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

OMT beneficial as adjunctive treatment in elderly people with pneumonia

OMT beneficial as adjunctive treatment in elderly people with pneumonia

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Experts discuss recent advancements in personalized medicine for treating childhood disorders

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.